Article Details

FDA approves Blueprint cancer drug for use in rare blood disease

Retrieved on: 2021-06-17 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

FDA approves Blueprint cancer drug for use in rare blood disease. View article details on hiswai:

Excerpt

... notably, Loxo Oncology and Array BioPharma, which were respectively bought for $8 billion and $11 billion — Blueprint has remained independent.

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo